Department of Medical Oncology, Vall d́Hebron Barcelona Hospital Campus, Barcelona, Spain; Vall d́Hebron Institute of Oncology, Barcelona, Spain.
Vall d́Hebron Institute of Oncology, Barcelona, Spain.
Cancer Treat Rev. 2024 Jul;128:102747. doi: 10.1016/j.ctrv.2024.102747. Epub 2024 Apr 27.
The advent of molecular profiling and the generalization of next generation sequencing in oncology has enabled the identification of patients who could benefit from targeted agents. Since the tumor-agnostic approval of pembrolizumab for patients with MSI-High tumors in 2017, different molecularly-guided therapeutics have been awarded approvals and progressively incorporated in the treatment landscape across multiple tumor types. As the number of tumor-agnostic targets considered druggable expands in the clinic, novel challenges will reshape the drug development field involving all the stakeholders in oncology. In this review, we provide an overview of current tumor-agnostic approvals and discuss promising candidate therapeutics for tumor-agnostic designation and challenges for their broad implementation.
随着分子谱分析的出现和下一代测序在肿瘤学中的广泛应用，能够识别出可能从靶向药物中获益的患者。自 2017 年 MSI-High 肿瘤患者的 pembrolizumab 获得肿瘤不可知批准以来，不同的分子指导治疗方法已获得批准，并在多种肿瘤类型的治疗领域中逐步得到应用。随着临床上可考虑进行药物治疗的肿瘤不可知靶点数量的增加，新的挑战将重塑涉及肿瘤学所有利益相关者的药物开发领域。在这篇综述中，我们概述了目前的肿瘤不可知批准，并讨论了有前途的肿瘤不可知指定候选治疗药物及其广泛实施的挑战。
